High-Potency Statin and Ezetimibe Use and Mortality in AMI
In conclusion, our study found that, compared with remaining on simvastatin monotherapy, switching to a high-potency statin (rosuvastatin or atorvastatin) was associated with a lower mortality risk. Whereas this does not appear to be the case in those patients who had ezetimibe added to a statin therapy.
Conclusion
In conclusion, our study found that, compared with remaining on simvastatin monotherapy, switching to a high-potency statin (rosuvastatin or atorvastatin) was associated with a lower mortality risk. Whereas this does not appear to be the case in those patients who had ezetimibe added to a statin therapy.